HIV pill heralds new era in fight against Aids

Health Editor,Jeremy Laurance
Wednesday 24 November 2010 01:00
Comments

Scientists yesterday announced the first anti-HIV pill to provide effective protection against the disease that affects 33 million people globally.

Gay men at extremely high risk of HIV who took the oral pill daily cut their risk of contracting the infection by almost 44 per cent. Aids organisations and researchers said it heralded a new era of Aids prevention. After the failure of almost 30 large-scale trials of protective therapies, recent positive results for an Aids vaccine and for a microbicidal gel suggest progress.

"This discovery alters the HIV prevention landscape for ever," said Jim Pickett of the Aids Foundation of Chicago. Anthony Fauci, head of the National Institute for Allergy and Infectious Diseases – which provided two thirds of the $43.6m (£27.6m) cost of the study – said: "The results are extremely important." Margaret Chan, director general of the World Health Organisation, said the trial opened "exciting new prospects".

Almost 2,500 men from the US, South Africa, Thailand, Brazil, Ecuador and Peru took part in the study. They were highly sexually-active, reporting an average of 18 partners over 12 weeks, with 60 per cent saying they had receptive, unprotected anal intercourse during that time, the riskiest sexual activity for HIV.

Half the men took the pill, called Truvada, containing an antiretroviral medicine, amongst whom there were 36 infections after 14 months. There were 64 infections among those who took a placebo, amounting to a 43.8 per cent reduction with Truvada. All the men received regular advice about how to reduce their risks, a supply of condoms and treatment for other sexually transmitted infections.

Kevin O'Reilly, an HIV prevention specialist at WHO, said the results were "somewhat weaker than had been hoped". Many of the men did not take the drug regularly and protection was highest in those who had the most consistent use.

He said side-effects were minor and compared the treatment to the use of oral contraceptives by women.

"It is only one ARV and the most easily tolerated compared with three taken by people who are HIV-positive and on treatment. Its safety has been very well studied."

The preventive strategy is also being trialled in heterosexuals in Africa and injecting drug users in Thailand and the results are expected next year.

Experts accept that every extra preventive measure may encourage riskier behaviour but they say the more weapons against the disease the better. Problems with compliance may mean the drug has to be delivered in a different form, for example as a microbicidal gel to be used during intercourse.

Sir Nick Partridge of the Terence Higgins Trust said: "It's not ready for widespread use yet. Three major hurdles are still going to be: its cost, the risks of drug-resistant strains of HIV developing and taking a drug treatment every day.

"For now – and for the foreseeable future – condoms remain the most effective, easily available and cheapest way of preventing HIV transmission."

Register for free to continue reading

Registration is a free and easy way to support our truly independent journalism

By registering, you will also enjoy limited access to Premium articles, exclusive newsletters, commenting, and virtual events with our leading journalists

Please enter a valid email
Please enter a valid email
Must be at least 6 characters, include an upper and lower case character and a number
Must be at least 6 characters, include an upper and lower case character and a number
Must be at least 6 characters, include an upper and lower case character and a number
Please enter your first name
Special characters aren’t allowed
Please enter a name between 1 and 40 characters
Please enter your last name
Special characters aren’t allowed
Please enter a name between 1 and 40 characters
You must be over 18 years old to register
You must be over 18 years old to register
Opt-out-policy
You can opt-out at any time by signing in to your account to manage your preferences. Each email has a link to unsubscribe.

Already have an account? sign in

By clicking ‘Register’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Join our new commenting forum

Join thought-provoking conversations, follow other Independent readers and see their replies

Comments

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged in